Navegando por Palavras-chave "Inibidores de Hidroximetilglutaril-CoA Redutases"

Agora exibindo 1 - 3 de 3
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Efeitos agudos e cronicos da terapia hipolipemiante nos niveis circulantes de celulas progenitoras endoteliais e microparticulas
    (Universidade Federal de São Paulo (UNIFESP), 2011) Franca, Carolina Nunes [UNIFESP]
    Celulas progenitoras endoteliais e microparticulas sao associadas ao risco cardiovascular. Objetivos: Foram comparados efeitos agudos da Introdução e suspensao de duas estrategias hipolipemiantes nos niveis de celulas progenitoras endotelias e de microparticulas endoteliais e plaquetarias em coronarianos estaveis (subestudo 1), e efeitos cronicos nos mesmos parametros para outras duas estrategias hipolipemiantes em pacientes com aterosclerose carotidea (subestudo 2). Metodos: No subestudo 1 foram empregadas atorvastatina 80 mg/d ou rosuvastatina 40 mg/d. No subestudo 2, foram utilizadas atorvastatina 80 mg/d ou combinacao de ezetimiba 10 mg + atorvastatina 20 mg/d, por seis meses. Celulas progenitoras endoteliais e microparticulas foram quantificadas por citometria de fluxo, utilizando-se anticorpos especificos. Resultados: No subestudo 1, a atorvastatina ou sua suspensao nao modificou as subpopulacoes de progenitoras endoteliais, porem rosuvastatina 40 mg/d associou-se a aumento na subpopulacao CD34+/CD133+ (p=0,02). Neste subestudo, terapia ou suspensao da atorvastatina nao influenciou o numero de microparticulas endoteliais ou plaquetarias, porem apos suspensao da rosuvastatina observou-se aumento no numero de microparticulas plaquetarias (p=0,01) e tendencia a aumento de microparticulas endoteliais (p=0,05). No subestudo 2, nao houve diferenca nos titulos de progenitoras endoteliais apos seis meses de terapia nos dois subgrupos. Neste subestudo, houve aumento de microparticulas plaquetarias (p=0,001) com atorvastatina, sem alteracao nas microparticulas endoteliais. No subgrupo da atorvastatina combinada ao ezetimiba, houve aumento de microparticulas endoteliais (p=0,03) e tendencia a aumento de microparticulas plaquetarias (p=0,06). Conclusoes: Terapia hipolipemiante aguda ou cronica modificou niveis circulantes de celulas progenitoras endoteliais e microparticulas endoteliais e plaquetarias, sendo esses efeitos influenciados pela estrategia hipolipemiante adotada
  • Imagem de Miniatura
    Item
    Embargo
    Estudo duplo-cego, placebo-controlado, do uso da fluvastatina sobre a pressão arterial, a sensibilidade à insulina e a morfologia cardiovascular em pacientes portadores de hipertensão arterial
    (Universidade Federal de São Paulo (UNIFESP), 2009-01-27) Teixeira, Andrei Alkmim [UNIFESP]; Tavares, Agostinho [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)
    Among hypertensive patients, cardiovascular disease morbidity is common, even in those who are adequately treated. New pharmacologic strategies to mitigate the burden of arterial hypertension are needed. This 12-month, randomized, double-blind placebocontrolled study investigated the effect of statin (fluvastatin) treatment on ambulatory blood pressure (ABP), exercise blood pressure (EBP), myocardial structure, endothelial function and insulin resistance in 50 hypertensive patients. At baseline, the groups were comparable in terms of demographic characteristics, ABP, EBP, endothelial function and homeostasis model assessment of insulin resistance (HOMAIR). At the end of the study, there was no difference between groups in terms of resting systolic blood pressure. However, maximum systolic EBP was lower in the treatment group than in the placebo group (175 ± 18 mmHg vs. 192 ± 23 mmHg, P < 0.05), as was left ventricular mass index (LVMI; 82 ± 15 vs. 100 ± 23, P < 0.05) and HOMA-IR index was lower after fluvastatin treatment (2.77 ± 1.46 vs. 3.33 ± 1.73, P < 0.05). Changes in lipid profile were not correlated with blood pressure, endothelial function, LVMI, or HOMA-IR data. In hypertensive patients, fluvastatin can improve maximum systolic EBP, myocardial remodeling and insulin resistance, independently on lipid profile variations and endothelial function.
  • Imagem de Miniatura
    Item
    Acesso aberto (Open Access)
    Treatment of Dyslipidemia with Statins and Physical Exercises: Recent Findings of Skeletal Muscle Responses
    (Sociedade Brasileira de Cardiologia - SBC, 2015-01-01) Bonfim, Mariana Rotta; Oliveira, Acary Souza Bulle [UNIFESP]; Amaral, Sandra Lia do; Monteiro, Henrique Luiz; Universidade Estadual Paulista (UNESP); Universidade Federal de São Paulo (UNIFESP)
    Statin treatment in association with physical exercise practice can substantially reduce cardiovascular mortality risk of dyslipidemic individuals, but this practice is associated with myopathic event exacerbation. This study aimed to present the most recent results of specific literature about the effects of statins and its association with physical exercise on skeletal musculature. Thus, a literature review was performed using PubMed and SciELO databases, through the combination of the keywords “statin” AND “exercise” AND “muscle”, restricting the selection to original studies published between January 1990 and November 2013. Sixteen studies evaluating the effects of statins in association with acute or chronic exercises on skeletal muscle were analyzed. Study results indicate that athletes using statins can experience deleterious effects on skeletal muscle, as the exacerbation of skeletal muscle injuries are more frequent with intense training or acute eccentric and strenuous exercises. Moderate physical training, in turn, when associated to statins does not increase creatine kinase levels or pain reports, but improves muscle and metabolic functions as a consequence of training. Therefore, it is suggested that dyslipidemic patients undergoing statin treatment should be exposed to moderate aerobic training in combination to resistance exercises three times a week, and the provision of physical training prior to drug administration is desirable, whenever possible.